Relationships between biochemical and symptomatic response in a double- blind randomised trial of pamidronate for metastatic bone disease

Annals of Oncology

Volumn 8, Issue 12, 1997, Pages 1243-1250

  Vinholes, J J F ^a   Prakash Purohit, O ^a   Abbey, M E ^a   Eastell, R ^b   Coleman, R E ^a,b  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Bisphosphonates; Bone metastases; Bone resorption; Pyridinium cross links

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; CODEINE; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; HYDROXYPROLINE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PAMIDRONIC ACID; PLACEBO; PYRIDINOLINE; SODIUM CHLORIDE;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BONE RADIOGRAPHY; BONE TURNOVER; BREAST CANCER; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; COLLAGEN DEGRADATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYDROXYPROLINE URINE LEVEL; INTRAVENOUS DRUG ADMINISTRATION; MALE; OSTEOLYSIS; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 7144264425     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008238422151     Document Type: Article

References (39)

1. Purohit OP, Kanis J, Coleman R et al. Randomised double-blind comparison of single infusions of pamidronate or clodronate for hypercalcaemia of malignancy. Br J Cancer 1995; 72: 1289-93.
2. Berenson J, Lichtenstein A, Knight R et al. for the Myeloma Aredia Study Group. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 1996; 334: 488-93.
3. Hortobagyi GN, Porter L, Reitsma DJ et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic metastases. N Engl J Med 1996; 335: 1785-91.
4. Conte PF, Giannessi PG, Mauriac L et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: Results from a multinational randomised controlled trial. J Clin Oncol 1996; 14: 2552-9.
5. Lahtinen R, Laasko M, Elomaa et al. for the Finnish Leukaemia Group. Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet 1992; 340: 1049-52.
6. Purohit OP, Anthony C, Coleman RE et al. High-dose intravenous pamidronate for metastatic bone pain. Br J Cancer 1994; 70: 554-8.
7. Ernst DS, MacDonald RN, Paterson AHG et al. A double-blind cross-over trial of i.v. clodronate in metastatic bone pain. J Pain Sympt Man 1992; 7: 4-11.
8. Coombes RC, Dady P, Powles J et al. Assessment of response of bone metastases to systemic therapy. Cancer 1983; 52: 610-4.
9. Coleman R, Rubens R, Fogelman I. The bone scan flare following systemic therapy for bone metastases. J Nucl Med 1988; 29: 1354-9.
10. Coleman RE. Evaluation of bone disease in breast cancer. The Breast 1994; 3: 73-8.
11. Coleman RE, Whitaker KD, Rubens RD et al. Biochemical monitoring predicts response in bone to systemic treatment. Br J Cancer 1988; 58: 205-10.
12. Blomqvist C, Elomaa I, Risteli J et al. The response evaluation of bone metastases in mammary carcinoma. The value of radiology, scintigraphy and biochemical markers of bone metabolism. Cancer 1987; 60: 2907-12.
13. Hanson DA, Weis MAE, Bollen AM et al. A specific immunoassay for monitoring human bone resorption: Quantification of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992; 7: 1251-8.
14. Bonde M, Qvist P, Christiansen C et al. Applications of an enzyme immunoassay for a new marker of bone resorption (Crosslaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995; 80: 864-8.
15. Robins SP, Woitge H, Hesley R et al. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Min Res 1994; 9: 1643-9.
16. Gertz BJ, Shao P, Eyre DR et al. Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Min Res 1994; 9: 135-42.
17. Garnero P, Shin W, Delmas P et al. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994; 79: 1693-700.
18. Campodarve U, Ulrich N, Chesnut C et al. Urinary N-telopeptide of type I collagen monitors bone resorption and may predict change in bone mass of the spine in response of hormone replacement therapy. J Bone Min Res 1995; 10 (Suppl 1): S182.
19. Paterson CR, Robins SP, Cuschieri A et al. Pyridinium crosslinks as markers of bone resorption in patients with breast cancer. Br J Cancer 1991; 64: 884-6.
20. Sano M, Kushida K, Ohishi T et al. Urinary pyridinoline and deoxypyridinoline in prostate carcinoma patients with bone metastases. Br J Cancer 1994; 70: 701-3.
21. Lipton A, Demers L, Seyedin S et al. Increased urinary excretion of pyridinium cross-links in cancer patients. Clin Chem 1993; 39: 614-8.
22. Pecherstorfer M, Ludwig H, Seibel M et al. The diagnostic value of urinary pyridinium cross-links of collagen, alkaline phosphatase and urinary calcium excretion in neoplastic bone disease. J Clin Endocrinol Metab 1995; 80: 97-103.
23. Myamoto KK, McSherry SA, Robins SP et al. Collagen cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol 1994; 151: 909-13.
24. Takeuchi S, Yoshida K. Assay of urinary pyridinoline and deoxypyridinoline as potential markers of the rate of bone resorption: Usefulness in patients with prostate cancer with bone metastases. Jpn J Urol 1994; 85: 1521-7.
25. Eyre DR, Koob TJ, Van Ness KP. Quantification of hydroxypyridinium cross-links in collagen by high performance liquid chromatography. Ann Biochem 1984; 137: 380-8.
26. Colwell A, Russell RGG, Eastell R. Factors affecting the assay of urinary 3-hydroxy pyridinium cross-links of collagen as markers of bone resorption. Eur J Clin Invest 1993; 23: 341-9.
27. Vinholes J, OP Purohit, Eastell R, Coleman R et al. Randomised double-blind comparison of pamidronate or clodronate for hypercalcaemia of malignancy: Effects on bone metabolism markers. J Clin Oncol 1997; 15: 131-8.
28. De Haes JCM, Knippenberg FCE, Neijt JP. Measuring psychological distress in cancer patients: Application of the Rotterdam Symptom Checklist. Br J Cancer 1990; 62: 1034.
29. Tyrrell CJ on behalf of the Aredia Multinational Cooperative Group Role of pamidronate in the management of bone metastases from breast cancer: Results of a non-comparative multicenter phase II trial. Ann Oncol 1994; 5 (Suppl 7): 37-410.
30. Powles TJ, Rosset G, Leese CL et al. Early morning hydroxyproline excretion in patients with breast cancer. Cancer 1976; 38: 2564-6.
31. Coombes RC, Dady P, Powles T et al. Assessment of response of bone metastases to systemic therapy. Cancer 1983; 52: 610-4.
32. Vinholes J, Eastell R, Coleman R et al. Metabolic effects of pamidronate in patients with metastatic bone disease. Br J Cancer 1996; 73: 1089-95.
33. Percival RC. Skeletal effects of carcinoma of breast and prostate. Ann Royal Coll Surg Engl 1986; 68: 267-70.
34. Coleman RE: Assessment of response to treatment. In: Rubens RD, Fogelman I (eds): Bone metastases - diagnosis and treatment. London, UK: Springer-Verlag 1991; 11-30.
35. Clarke NW, Holbrook IB, McClure J et al. Osteoclast inhibition by pamidronate in metastatic prostate cancer: A preliminary study. Br J Cancer 1991; 63: 420-3.
36. Coleman RE, Houston S, Ford J et al. Preliminary results of the use of urinary excretion of pyridinium cross-links for monitoring metastatic bone disease. Br J Cancer 1992; 65: 766-8.
37. Roux C, Ravaud P, Amor B et al. Biologic, histologic and densitometric effects of oral residronate on bone in patients with multiple myeloma. Bone 1994; 15: 41-9.
38. Downey S, Walls J, Eastell R et al. Pyridinoline excretion can monitor bone metastases in breast cancer. Breast Cancer Res Treat 1994; 32 (Suppl 1): 83.
39. Demers LM, Costa L, Lipton A et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995; 41: 1489-94.